Comparative Effectiveness Research Not Aligned with Financial Incentives
The RAND researchers picked six major studies from the last decade that produced findings that should have dramatically altered the way patients with certain conditions, such as stable coronary artery disease, schizophrenia, hypertension, or lumbar spinal stenosis, should be treated.
They then identified several steps by which traditional research should be translated into practice, for example, from interpretation to formalization—when the findings are converted to guidelines and performance measures or clinical decision support tools—to dissemination to implementation.
But after three of the studies, there was "no change in practice," and in two there was merely "some" or "little change" in practice or "slow adoption."
For example, the ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial), published in 2002, found that for patients with hypertension and at least one other cardiovascular disease risk factor, "less costly, traditional diuretics are more effective than newer medicines at lowering high blood pressure and preventing some forms of heart disease," according to the National Heart, Lung, and Blood Institute.
Timbie, however, found that these less expensive diuretics "are adopted much more slowly than heavily marketed treatments that are less effective."
Similarly, the 2007 COURAGE trial, (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) revealed that medical therapy and percutaneous coronary intervention (PCI) did not provide patients with better survival benefit and angina relief than medical therapy alone. Yet there has been "little or no change in practice," Timbie says.
- CEO Exchange: Preparing for Population Health
- Advocate, NorthShore Deal Would Create 16-Hospital System
- Better HCAHPS Scores Protect Revenue
- 3 Strategies for Retaining Millennial Employees
- Narrow Networks Cut Costs, Not Quality, Economists Say
- Power of price: In South FL and the nation, healthcare costs often are shrouded in secrecy
- Hospital mergers may lead to higher prices
- Healthcare data of 1 million NJ patients compromised since 2009
- CEO Exchange: Pressure is On to Partner, Drive Quality